The use of immunotherapy in advanced non-small cell lung cancer (NSCLC) has long been investigated in advanced NSCLC. The frequent presence of tumor infiltrating lymphocytes (TILs) noted in numerous tumor types provided early evidence of the potential immunogenicity of several cancers including NSCLC.
Touch MEdical MEdia
The use of immunotherapy in advanced non-small cell lung cancer (NSCLC) has long been investigated in advanced NSCLC. The frequent presence of tumor infiltrating lymphocytes (TILs) noted in numerous tumor types provided early evidence of the potential immunogenicity of several cancers including NSCLC. 1, 2 However, initial attempts to exploit this therapeutically through tumor vaccines, interleukin (IL)-2, interferon, and similar immunotherapies were generally met with limited success. 3, 4 The significant clinical benefit from cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immune checkpoint inhibitors found in melanoma led to clinical trials of ipilimumab attempting to demonstrate similar benefit in NSCLC. 5 Although modest activity was demonstrated with both ipilimumab and certain vaccine-based therapeutic strategies and some clinical trials are still ongoing, [5] [6] [7] [8] [9] [10] [11] there has been pessimism in the field regarding the utility of immunotherapy in NSCLC.
The development of programmed cell death protein 1 (PD- 
Immunogenicity and Mechanisms of Immune Escape in NSCLC
The tumor stroma consists of a complex infiltrate of various cell types including both inflammatory cells and TILs. 2 The presence of this immune infiltrate provided early evidence of the potential relationship between the immune system and several tumor types including NSCLC. The composition of the immune infiltrate associated with NSCLC exhibits variability between
patients. An increased proportion of TILs relative to other inflammatory cells in the tumor stroma have been associated with improved prognosis in both the prospective and retrospective cohorts of patients with advanced NSCLC. 12 Conversely, an increased proportion of T regulatory cells (TREGs) relative to cytotoxic T lymphocytes (CTLs) has been associated with a poorer prognosis in advanced NSCLC. 13 The secretion of specific chemokines has been suggested to directly recruit TREGs to the tumor microenvironment with subsequent blunting of any potential anti-tumor immune response. , and the PD-1 pathway. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] The PD-1 pathway has emerged as a key checkpoint of interest in NSCLC due to both the frequency of PD-L1 expression in this tumor type well as early evidence suggesting significant clinical activity using PD-1 pathway inhibitors.
PD-L1 Overexpression and Evasion of the T-cell-mediated Immune Response in NSCLC
PD-1 is expressed on the surface of activated T cells and serves primarily to dampen the effector function of T cells through interaction with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC). 18, [26] [27] [28] [29] [30] Interaction of PD-1 with its ligand results in downregulation of T-cell-mediated cell killing, altered cytokine production, and, ultimately, apoptosis. 15, 17, 26, 29, 30 PD-L1 is expressed in various normal tissues in response to inflammatory cytokine signaling in order to maintain self-tolerance. This same mechanism is coopted by tumor cells in order to avoid an acquired immune response to tumor-associated antigens. 19, 20 The overexpression of PD-L1 by tumor cells in NSCLC has been demonstrated in several large retrospective studies. The largest of these studies examined archived tumor tissue from 458 patients with stage I-IV NSCLC across all histologies using quantitative immunofluorescence (QIF) to detect PD-L1 expression on the tumor cell surface. 1 This revealed that 32 % of these samples expressed elevated PD-L1. Similar smaller retrospective studies in NSCLC using both QIF and immunohistochemistry (IHC) have reported rates of PD-L1 expression by tumor cells ranging from 27 to 58 %. Several of these studies report an increased inflammatory infiltrate associated with PD-L1 overexpression. [31] [32] [33] [34] [35] [36] The expression of PD-L1 by tumor cells may also be mediated by the activation of specific oncogenes associated with NSCLC including epidermal growth factor receptor (EGFR) and KRAS although the relationship with the latter remains controversial. 31, [37] [38] [39] Smoking status has also been correlated with elevated PD-L1 expression. 39 However, association between overall survival (OS) and PD-L1 expression remains controversial with reports of both an associated improvement and decrease in OS. [31] [32] [33] [34] PD-L1 overexpression and associated activation of the PD-1 pathway thus appears to be broadly exploited by tumor cells in NSCLC as a means to evade T-cell-mediated anti-tumor activity. The observed high rate of PD-L1 overexpression in NSCLC occurs across both disease stage and histology.
In particular, high rates of overexpression have been reported in both squamous cell and sarcomatoid lung cancer. OncOlOgy & HematOlOgy Review between these various agents is challenging with respect to both clinical activity and toxicity. We will review the current agents that have entered into later phase clinical trials including preliminary data on their activity and toxicity (see Table 1 ). However, we would caution against drawing any major distinction between the activity and toxicity of these agents until more published data is available.
Blockade of either programmed cell death protein 1 (PD-1) (nivolumab, pembrolizumab) or programmed death-ligand 1 (PD-L1) (MPDL3280A, MEDI4736) are designed to enhance immunemediate tumor cell killing by disrupting this signaling. Current predictive biomarkers for these agents include PD-L1 overexpression on either (i) the tumor cell surface or (ii) the surface of tumor infiltrating immune cells, such as dendritic cells. MHC = major histocompatibility complex; TCR = T cell receptor.

Nivolumab (BMS-936558, Opdivo)
The and occasional infusion reactions (1 %). However, early data indicates that this agent is generally well tolerated. The updated results of the expanded phase I study of nivolumab in advanced NSCLC revealed significant and durable activity of this agent among 129 heavily pretreated patients. An objective response rate of 17 % was reported across all dose cohorts with a median response duration of 17 months. 42 A similar overall response rate (ORR) was noted between PD-L1 negative and PD-L1 positive patients, using a 5 % threshold for determining positive expression.
These initial early phase data were the first to clearly demonstrate the promise of this class of agents and their acceptable toxicity profile.
The tantalizing possibility that these agents may yield durable treatment responses with minimal toxicity even in heavily pretreated patients has led to the rapid proliferation of multiple PD-1 and PD-L1 inhibitors. Several phase II and III studies of nivolumab in advanced NSCLC have been initiated since the completion of the aforementioned phase I study (see Table 2 ). The makers of nivolumab have announced that the CheckMate 017 phase III trial of nivolumab versus docetaxel in the second-line treatment of advanced squamous cell lung cancer has been stopped early due to significant OS benefit in the nivolumab arm. 43 Nivolumab has received approval for use in metastatic melanoma refractory to ipilimumab in Japan. 44 
Pembrolizumab (MK-3475, Keytruda)
Pembrolizumab is a humanized IgG4 monoclonal antibody against PD-1.
It is currently being examined in both multiple phase I trials as well as Table 2 ).
MEDI4736
MEDI4736 is a human IgG1k monoclonal antibody directed against PD-L1.
Similar to previous agents, preliminary phase I trial data demonstrate an ORR of 16 % among 58 evaluable pretreated advanced NSCLC patients. 
Rationale for Combination Therapy and Ongoing Trials
Early data indicating significant clinical activity and manageable toxicity associated with PD-1 and PD-L1 inhibitors has led not only to rapid proliferation of single-agent later-phase trials, but a multitude of trials evaluating the combination of these inhibitors with various other agents.
Broadly, these combinations fall into several main classes including combined immune checkpoint blockades, tyrosine kinase inhibitor (TKI)
combinations, and combinations with chemotherapy.
Combined Immune Checkpoint Blockade
This strategy utilizes the biologic rationale that multiple mechanisms may be exploited simultaneously by tumor cells in order to evade anti-tumor immune activity. As such, it has been proposed that combining PD-1 or PD-L1 inhibitors with antibodies directed against other immune checkpoints including CTLA4, KIR, lymphocyte activation gene-3 protein (LAG-3), or TIM-3 may enhance T lymphocyte and NK cell-mediated anti-tumor activity. The combination of PD-1 and CTLA4 inhibitors has demonstrated promising activity in metastatic melanoma. 51 However, the increased toxicity of this combination and limited single-agent activity of ipilimumab in advanced NSCLC in contrast to melanoma makes the combination still of uncertain benefit in NSCLC. 5, 51 The more novel combination of PD-1 inhibitors and anti-KIR, anti-LAG3, and anti-IDO antibodies has also entered early clinical development (see Table 3 ).
PD-1/PD-L1 Inhibition and Tyrosine Kinase Inhibitor
The combined inhibition of both the PD-1/PD-L1 immune checkpoint as well as aberrant cell signaling secondary to an underlying driver mutation is a particularly promising treatment approach in advanced NSCLC.
Several targetable oncogenic driver mutations have been identified in lung adenocarcinoma including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF mutations. 52 An increasing number of TKIs have been developed that are able to specifically target these mutations with significant clinical activity. Further, emerging preclinical data suggests a potential interplay between PD-L1 overexpression and abnormal EGFR signaling. 37 It has thus been theorized that significant As such, various combinations of these inhibitors with kinase inhibitors targeting both EGFR and MEK signaling in mutant selected populations are currently underway (see Table 3 ) with trials of combined therapy with ALK inhibitors in the planning stages as well.
PD-1/PD-L1 Inhibition and Chemotherapy
The use of standard chemotherapy combined with PD-1/PD-L1 inhibition has been proposed as a potential means of enhancing therapeutic efficacy.
The combination of these agents has been postulated to allow for both nonspecific cytotoxic reduction of tumor burden followed by immune- Table 3 ).
Key Questions in the Use of PD-1/PD-L1 Inhibitors Biomarkers
Perhaps the most controversial matter surrounding the development of PD-1 and PD-L1 inhibitors has been the use of PD-L1 expression as a predictive biomarker. It follows logically that PD-L1 expression levels on the surface of tumor cells would predict the activity of these inhibitors based on the biology that we have previously outlined. However, early studies of the activity of these agents across all four major commercial drugs in development in NSCLC indicate a variable degree of association between PD-L1 expression and clinical activity of these agents.
Even in trials where increased expression does correlate with increased activity, a modest rate of treatment response is also seen in PD-L1- negative patients. The use of multiple antibodies to detect PD-L1 as well as variable definitions of the IHC threshold that constitutes PD-L1 positivity further complicates this matter. This is illustrated by the reported finding in the early-phase study of pembrolizumab in advanced NSCLC, which reported increasing ORR at high thresholds of PD-L1 positivity (>50 %). 46 
Use of Immune Response Criteria
Another main area of controversy in the development of clinical trials for these agents has been the use of strict RECIST 1.1 criteria for the interpretation of ORR. Early phase trials of these agents have suggested that a subset of patients may experience initial increases in tumor size secondary to anti-tumor immune activity, which ultimately leads to subsequent tumor regression or long-term disease stability (pseudoprogression). The re-biopsy of such pseudoprogressed lesions has been reported to yield predominantly inflammatory material consistent with a robust anti-tumor immune response. 53 The time period over which these agents act may thus complicate the interpretation of strict ORR using established RECIST 1.1 criteria. Efforts to utilize immune-related response criteria provide an important method to better understand this phenomenon and many current trials have allowed continued treatment beyond RECIST-defined progression (see Table 4 ). 54 More exact rules regarding the interpretation of response and appropriate treatment discontinuation guidelines for these agents will be required should they transition to use outside of the research context in the future. The need for such consensus criteria is particularly urgent given the recent FDA approval of pembrolizumab for use in metastatic melanoma-a situation that may lead to its premature off-label use in NSCLC.
47
Summary
The development of PD-1 and PD-L1 inhibitors has generated significant enthusiasm and unprecedentedly rapid design of later phase trials of these agents and combination drug studies. The potential for these agents to provide clinical benefit to NSCLC patients with manageable toxicity is considerable-particularly among cancers lacking oncogenic drivers and squamous cell lung cancers where few good treatment options exist. Early results from phase I clinical trials indicate potential clinical activity even in heavily pretreated advanced NSCLC with rare but serious incidences of pneumonitis. However, extremely limited data exist on the potential survival benefit of these agents either alone or in combination with other drug classes. The role of PD-L1 expression as a predictive biomarker for these agents remains controversial. The potential of these agents to achieve long-term disease control when combined with other immune checkpoint or kinase inhibitors remains a tantalizing possibility. We await the outcome of the aforementioned studies in order to definitively answer these pending questions regarding the real benefit of these agents and the appropriate biomarker selected population in which they should be employed. n
